11.10 07:05 | dpa-AFX: ROUNDUP/Experten: Arzneiengpass nicht identisch mit Versorgungslücke |
11.10 07:05 | ROUNDUP/Experten: Arzneiengpass nicht identisch mit Versorgungslücke |
11.10 07:00 | dpa-AFX: ROUNDUP/Experten: Arzneiengpass nicht identisch mit Versorgungslücke |
04.10 06:38 | dpa-AFX: *ABL BIO ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ABL103 WITH KEYTRUDA IN PATIENTS WITH SOLID TUMORS |
01.10 12:53 | dpa-AFX: *MERCK COMPLETES ACQUISITION OF CN201 FROM CURON BIOPHARMA |
25.09 14:44 | MÄRKTE USA/Wall Street zurückhaltend zum Start erwartet |
25.09 13:17 | dpa-AFX: Merck Says Phase 3 KEYFORM-007 Study Did Not Meet Primary Goal Of Overall Survival |
25.09 12:57 | dpa-AFX: *MERCK SAYS PHASE 3 KEYFORM-007 TRIAL FAILS TO MEET PRIMARY ENDPOINT OF OVERALL SURVIVAL |
25.09 12:56 | dpa-AFX: Merck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLC |
25.09 12:46 | dpa-AFX: *MERCK'S KEYTRUDA GETS NEW APPROVALS IN JAPAN FOR PATIENTS WITH NSCLC AND RADICALLY UNRESECTABLE UROTHELIAL CARCINOMA |
24.09 16:16 | dpa-AFX: Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus |
18.09 13:52 | dpa-AFX: Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults |
18.09 13:20 | dpa-AFX: *MERCK: FDA APPROVES KEYTRUDA PLUS PEMETREXED AND PLATINUM CHEMOTHERAPY FOR ADULT PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA |
18.09 11:44 | dpa-AFX: Merck & Co To Present At Bank Of America Global Healthcare Conference; Webcast At 6:40 AM ET |
17.09 18:21 | MÄRKTE USA/Börsen mit leichten Aufschlägen |
17.09 12:45 | dpa-AFX: Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study |
17.09 12:08 | dpa-AFX: *DAIICHI SANKYO AND MERCK: HERTHENA-LUNG02 PHASE 3 TRIAL OF PATRITUMAB MEETS PRIMARY ENDPOINT |
15.09 18:54 | dpa-AFX: Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial |
12.09 13:35 | dpa-AFX: Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours |
12.09 13:03 | dpa-AFX: *HEALTH CANADA APPROVES KEYTRUDA AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC MSI-H OR DMMR SOLID TUMOURS |
|